All In Biotech

Drug Trial Radar · NCT00054587

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects

Last checked: Nov 19, 2026Latest source record: Jul 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,010 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,010

Actual

Start

Jun 2001

Primary completion

Jun 2009

Study completion Dec 2009

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 6, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of chemotherapy plus radiation therapy with or without trastuzumab is more effective in treating breast cancer. PURPOSE: Randomized phase III trial to compare two different chemotherapy regimens plus radiation therapy with or without trastuzumab in treating women who have breast cancer that has spread to lymph nodes in the axilla (under the arm).

Conditions

  • Breast Cancer

Interventions

  • TrastuzumabBiological

    8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)

  • CyclophosphamideDrug

    500 mg/m², D1 and every 3 weeks

  • docetaxelDrug

    on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks

  • EpirubicinDrug

    100 mg/m², D1 and every 3 weeks

  • FluorouracilDrug

    500 mg/m², D1 and every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free SurvivalTime frame: 5 years from randomization

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Paul Papin

    Angers, France

  • Centre Hospitalier d'Annecy

    Annecy, France

  • Institut Bergonie

    Bordeaux, France

  • C.H. Bourg En Bresse

    Bourg-en-Bresse, France

  • Centre Regional Francois Baclesse

    Caen, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Hopital Intercommunal De Creteil

    Créteil, France

  • Centre de Lutte Contre le Cancer Georges-Francois Leclerc

    Dijon, France

  • Institut Prive de Cancerologie

    Grenoble, France

  • Clinique du Petit Colmouilins

    Harfleur, France

  • Centre Hospitalier de Lagny

    Lagny-sur-Marne, France

  • Hopital Andre Mignot

    Le Chesnay, France

  • CMC Les Ormeaux

    Le Havre, France

  • Institut J. Paoli and I. Calmettes

    Marseille, France

  • Centre Hospitalier Regional Metz Thionville

    Metz, France

  • Centre Hospitalier General Andre Boulloche

    Montbéliard, France

  • Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

    Montpellier, France

  • Centre Hospitalier de Mulhouse

    Mulhouse, France

  • Centre Regional Rene Gauducheau

    Nantes-Saint Herblain, France

  • Hopital Avicenne

    Paris, France

  • Clinique Saint - Pierre

    Perpignan, France

  • CHU Poitiers

    Poitiers, France

  • Institut Jean Godinot

    Reims, France

  • Centre Eugene Marquis

    Rennes, France

  • Clinique Sainte Clotilde

    Sainte Clotilde, France

  • Centre Paul Strauss

    Strasbourg, France

  • Hopitaux Universitaire de Strasbourg

    Strasbourg, France

  • Institut Claudius Regaud

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.